Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00093951 is registered in ClinicalTrials.gov with Saegis Pharmaceuticals as lead sponsor.

NCT NCT00093951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00093951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase II Study of the Efficacy and Safety of SGS742 in Subjects With Mild to Moderate Alzheimer's Disease
Lead sponsor
Saegis Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2004
Completion date
September 30, 2007
Enrollment
280
Sites
59

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease